OSCAR FLORENDO: Open Payments
NPI 1174565568 · HIGH POINT, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,368 in 121 payments from 14 companies in 2025. Trend: 2023 $656 · 2024 $1,485 · 2025 $2,368
Food & beverage: $2,339Education: $29
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $543 |
| Corcept Therapeutics | 10 | $365 |
| Novo Nordisk Inc | 9 | $294 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $252 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 21 | $203 |
| Lilly USA, LLC | 8 | $187 |
| Amgen Inc. | 14 | $185 |
| AstraZeneca Pharmaceuticals LP | 2 | $159 |
| GlaxoSmithKline, LLC. | 4 | $74 |
| Neuronetics, Inc. | 1 | $30 |
Products named: Korlym, VRAYLAR, CAPLYTA, XIFAXAN, Ozempic, Wegovy, UBRELVY, FARXIGA.
Industry payments across NC — which companies pay providers there.
